Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + albumin-paclitaxel + toripalimab vs albumin-paclitaxel + toripalimab in advanced triple-negative breast cancer
ChiCTR2500110827Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of toripalimab and nab-paclitaxel in breast cancer (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
toripalimabnab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500110827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110827.